Guidance on the updates to reporting forms following implementation of the Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024.
Similar Posts
Clinical trials: Non-investigational medicinal products
Guidance on using non-investigational medicinal products in a clinical trial.
Research: Improving information supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs
Public Assessment Report on improving information regarding addiction, dependence, withdrawal, and tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs.
MHRA approves sebetralstat (Ekterly) to treat hereditary angioedema (HAE) attacks in patients aged 12 and over
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 15 July 2025, approved sebetralstat (Ekterly) for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older.
Field Safety Notices: 1 to 5 December 2025
List of Field Safety Notices from 1 to 5 Deceber 2025.
Clinical investigations for medical devices
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Field Safety Notices: 12 to 16 January 2026
List of Field Safety Notices from 12 to 16 January 2026.